Citius Pharmaceuticals, Inc. (CTXR) Financial Statements (2024 and earlier)
Company Profile
Business Address |
11 COMMERCE DRIVE CRANFORD, NJ 07016 |
State of Incorp. | NV |
Fiscal Year End | September 30 |
Industry (SIC) | 2834 - Pharmaceutical Preparations (benchmarking) |
More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) (USD)Annual | Quarterly
9/30/2023 Q4 | 6/30/2023 Q3 | 3/31/2023 Q2 | 12/31/2022 Q1 | 9/30/2022 Q4 | 6/30/2022 Q3 | 3/31/2022 Q2 | |||
---|---|---|---|---|---|---|---|---|---|
ASSETS | |||||||||
Current Assets | |||||||||
Cash, cash equivalents, and short-term investments | 33,281,830 | 29,065,522 | 36,887,251 | 41,711,690 | 48,044,194 | 55,756,232 | |||
Cash and cash equivalents | 33,281,830 | 29,065,522 | 36,887,251 | 41,711,690 | 48,044,194 | 55,756,232 | |||
Prepaid expense | 7,832,320 | 5,835,602 | 5,430,125 | 2,852,580 | 2,790,319 | 2,503,109 | |||
Total current assets: | 41,114,150 | 34,901,124 | 42,317,376 | 44,564,270 | 50,834,513 | 58,259,341 | |||
Noncurrent Assets | |||||||||
Operating lease, right-of-use asset | 503,817 | 552,205 | 599,617 | 646,074 | 691,593 | 736,209 | |||
Property, plant and equipment | 2,010 | 2,639 | 3,370 | 4,100 | 4,831 | 5,562 | |||
Intangible assets, net (including goodwill) | 9,346,796 | 9,346,796 | 9,346,796 | 9,346,796 | 9,346,796 | 9,346,796 | |||
Goodwill | 9,346,796 | 9,346,796 | 9,346,796 | 9,346,796 | 9,346,796 | 9,346,796 | |||
Other undisclosed noncurrent assets | 59,438,062 | 59,438,062 | 59,438,062 | 59,438,062 | 59,438,062 | 59,438,062 | |||
Total noncurrent assets: | 69,290,685 | 69,339,702 | 69,387,845 | 69,435,032 | 69,481,282 | 69,526,629 | |||
TOTAL ASSETS: | 110,404,835 | 104,240,826 | 111,705,221 | 113,999,302 | 120,315,795 | 127,785,970 | |||
LIABILITIES AND EQUITY | |||||||||
Liabilities | |||||||||
Current Liabilities | |||||||||
Accounts payable and accrued liabilities | 3,972,541 | 4,976,429 | 4,334,994 | 4,333,023 | 4,269,220 | 3,835,007 | |||
Employee-related liabilities | ✕ | ✕ | ✕ | 2,107,014 | 1,762,251 | 1,277,501 | 793,250 | ||
Accounts payable | 3,079,667 | 2,725,593 | 1,537,578 | 1,165,378 | 1,690,520 | 1,705,128 | |||
Accrued liabilities | 892,874 | 2,250,836 | 690,402 | 1,405,394 | 1,301,199 | 1,336,629 | |||
Other undisclosed current liabilities | 1,818,316 | 1,233,248 | 202,178 | 196,989 | 191,902 | 186,916 | |||
Total current liabilities: | 5,790,857 | 6,209,677 | 4,537,172 | 4,530,012 | 4,461,122 | 4,021,923 | |||
Noncurrent Liabilities | |||||||||
Long-term debt and lease obligation: | 481,245 | 532,883 | 582,302 | ||||||
Liabilities, other than long-term debt | 6,313,811 | 6,224,631 | 6,134,368 | 5,561,800 | 4,985,800 | 4,985,800 | |||
Deferred income tax liabilities | 5,993,800 | 5,849,800 | 5,705,800 | 5,561,800 | 4,985,800 | 4,985,800 | |||
Operating lease, liability | 320,011 | 374,831 | 428,568 | 481,245 | 532,883 | 582,302 | |||
Total noncurrent liabilities: | 6,313,811 | 6,224,631 | 6,134,368 | 6,043,045 | 5,518,683 | 5,568,102 | |||
Total liabilities: | 12,104,668 | 12,434,308 | 10,671,540 | 10,573,057 | 9,979,805 | 9,590,025 | |||
Equity | |||||||||
Equity, attributable to parent | 97,699,787 | 91,206,138 | 100,433,301 | 102,825,865 | 109,735,610 | 117,595,565 | |||
Common stock | 158,858 | 146,358 | 146,211 | 146,211 | 146,129 | 146,129 | |||
Additional paid in capital | 249,828,398 | 234,867,917 | 233,569,202 | 232,368,121 | 231,287,208 | 230,283,531 | |||
Accumulated deficit | (152,287,469) | (143,808,137) | (133,282,112) | (129,688,467) | (121,697,727) | (112,834,095) | |||
Equity, attributable to noncontrolling interest | 600,380 | 600,380 | 600,380 | 600,380 | 600,380 | 600,380 | |||
Total equity: | 98,300,167 | 91,806,518 | 101,033,681 | 103,426,245 | 110,335,990 | 118,195,945 | |||
TOTAL LIABILITIES AND EQUITY: | 110,404,835 | 104,240,826 | 111,705,221 | 113,999,302 | 120,315,795 | 127,785,970 |
Income Statement (P&L) (USD)Annual | Quarterly
9/30/2023 Q4 | 6/30/2023 Q3 | 3/31/2023 Q2 | 12/31/2022 Q1 | 9/30/2022 Q4 | 6/30/2022 Q3 | 3/31/2022 Q2 | ||
---|---|---|---|---|---|---|---|---|
Operating expenses | (8,672,112) | (10,685,300) | (7,249,883) | (7,549,566) | (8,916,652) | (7,590,625) | ||
Operating loss: | (8,672,112) | (10,685,300) | (7,249,883) | (7,549,566) | (8,916,652) | (7,590,625) | ||
Nonoperating income | 336,780 | 303,275 | 214,549 | 134,826 | 53,020 | 29,571 | ||
Investment income, nonoperating | 336,780 | 303,275 | 214,549 | 134,826 | 53,020 | 29,571 | ||
Interest and debt expense | 3,585,689 | |||||||
Other undisclosed loss from continuing operations before equity method investments, income taxes | ||||||||
Loss from continuing operations before income taxes: | (8,335,332) | (10,382,025) | (3,449,645) | (7,414,740) | (8,863,632) | (7,561,054) | ||
Income tax expense | (144,000) | (144,000) | (144,000) | |||||
Other undisclosed loss from continuing operations | (576,000) | |||||||
Loss from continuing operations: | (8,479,332) | (10,526,025) | (3,593,645) | (7,990,740) | (8,863,632) | (7,561,054) | ||
Loss before gain (loss) on sale of properties: | ✕ | ✕ | ✕ | ✕ | (7,990,740) | (8,863,632) | (7,561,054) | |
Income from discontinued operations | 3,585,689 | |||||||
Other undisclosed net loss | (3,585,689) | |||||||
Net loss attributable to parent: | (8,479,332) | (10,526,025) | (3,593,645) | (7,990,740) | (8,863,632) | (7,561,054) | ||
Other undisclosed net loss available to common stockholders, basic | ||||||||
Net loss available to common stockholders, diluted: | (8,479,332) | (10,526,025) | (3,593,645) | (7,990,740) | (8,863,632) | (7,561,054) |
Comprehensive Income (USD)Annual | Quarterly
9/30/2023 Q4 | 6/30/2023 Q3 | 3/31/2023 Q2 | 12/31/2022 Q1 | 9/30/2022 Q4 | 6/30/2022 Q3 | 3/31/2022 Q2 | ||
---|---|---|---|---|---|---|---|---|
Net loss: | (8,479,332) | (10,526,025) | (3,593,645) | (7,990,740) | (8,863,632) | (7,561,054) | ||
Comprehensive loss, net of tax, attributable to parent: | (8,479,332) | (10,526,025) | (3,593,645) | (7,990,740) | (8,863,632) | (7,561,054) |
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.